Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropathic Pain, Depression, and Analgesia Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for OPRD1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery (GPCR) | OPRD1 Lentivirus / Promise-ORF. Full-length ORF for stable cell line generation. HEK293 expressed, Endotoxin <1 EU/μg. Sequence Verified. | View OPRD1 Products |
| Antigen / Membrane Preparation | OPRD1 Membrane Extract or Stable Cell Line. HEK293 expressed, Native conformation and glycosylation preserved. High Purity (>95%). | View OPRD1 Products |
| Benchmark Ab | Anti-OPRD1 Recombinant Antibody (Reference Sequence). Sequence-defined positive control for binding assays. High Purity (>95%). | View OPRD1 Products |
| Validator | OPRD1 siRNA Set (Triple Targeting). For knockdown verification and assay specificity control. | View OPRD1 Products |
| Related Target A | OPRM1 (Mu Opioid Receptor). Critical for counter-screening and selectivity profiling. | View OPRM1 Products |
| Related Target B | OPRK1 (Kappa Opioid Receptor). Essential for off-target toxicity evaluation. | View OPRK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation Maintenance | Lentivirus-mediated stable cell expression (HEK293/CHO) for native membrane presentation, preserving 7-TM topology and glycosylation. |
| Subfamily Selectivity (Mu/Kappa vs Delta) | Sequence Verified OPRM1 and OPRK1 control reagents (human/mouse/cyno orthologs) available for rigorous counter-screening. |
| Biased Signaling Validation | Sequence-verified wild-type and phosphorylation-defective mutant (S130A) constructs for G-protein vs. β-arrestin pathway discrimination. |
| Lack of Positive Controls | Clinical Benchmark Antibodies included, strictly Endotoxin Controlled (<1 EU/μg). |
| False Positives in Signal Assays | Validated siRNA included for genetic specificity checks. |
Live OPRD1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for OPRD1 (Delta Opioid Receptor) therapeutics is intensifying as researchers seek alternatives to addictive Mu-opioid receptor agonists. Major players are shifting focus from traditional pan-opioid agonists to G-protein biased ligands, peripherally restricted antagonists, and heterodimeric receptor complexes. Key indications include neuropathic pain, migraine, major depressive disorder, Parkinson's disease, and opioid use disorder. The next wave of R&D targets biased agonism to separate therapeutic efficacy from pro-convulsant or tolerance-inducing side effects, alongside blood-brain barrier permeability optimization for CNS efficacy without respiratory liability. A notable naturally occurring variant (rs104211) enhances receptor maturation and cell surface expression, which may influence drug responsiveness and assay design. Engineered mutations such as S130A (GRK phosphorylation site) are used to dissect bias mechanisms and predict long-term tolerance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecules (Agonists & Antagonists) | Johnson & Johnson, Trevena, Kallyope, Alkermes | Depression, Pain, Addiction, Opioid Use Disorder | Selectivity Assay (Need OPRM1/OPRK1 counterscreening); Receptor occupancy assays with high-purity OPRD1 membranes |
| Biased Agonists | Kallyope, Trevena, Academic Spin-offs | Chronic Pain, Depression, Migraine, Analgesia | Pathway-selective cell lines (G-protein vs. β-arrestin recruitment); Functional assays (cAMP/β-arrestin via stable clones) |
| Peptide Therapeutics (including Bifunctional) | Emerging Biotechs | Neuropathic Pain, GI Motility Disorders | Receptor Binding (Need high-fidelity cell lines); Internalization assays (Need high-confluence OPRD1+ stable cell lines) |
Key Mutations & Assay Strategies
Understanding receptor mutations is critical for developing robust assays and interpreting drug effects:
- rs104211 (improved maturation & expression): This naturally occurring SNP (dbSNP:rs104211) increases OPRD1 cell surface expression and maturation. Assays using wild-type vs. variant may show different potency/efficacy. TarMart provides sequence-verified constructs for both variants to control for expression-level artifacts.
- S130A (phosphorylation-defective): Eliminates GRK-mediated phosphorylation, leading to prolonged G-protein signaling but reduced β-arrestin recruitment. Useful for biased agonist characterization and tolerance prediction.
- T80A (ligand binding pocket): Alters binding affinity for certain ligands. Incorporating this mutant in selectivity panels helps identify liability for resistance.
- Heterodimer context: OPRD1-OPRM1 co-expression (available via TarMart dual-gene lentivirus) is essential for detecting ligand bias shifts in heterodimers.
TarMart's lentivirus platform enables stable expression of wild-type and mutant receptors in HEK293/CHO cells, preserving native conformation and glycosylation for reliable functional and binding assays.
Future Directions
Next-generation developments include: (1) Bias factor quantification using standardized BRET/PathHunter assays; (2) Heterodimer-targeted drugs; (3) Peripheral restriction via P-gp substrate optimization; (4) Combination therapies leveraging OPRD1's neuroprotective effects to offset Mu-opioid side effects. TarMart's orthogonal assay solutions (lentivirus, membranes, antibodies, siRNA) equip researchers for each of these challenges.